N

    Novocure Ltd (NVCR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $17.65
    -0.17 (-0.95%)

    Market Cap: $2.08B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -42.10%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.32 - $-0.14
    7 analysts
    EPS Revisions
    5
    0
    7d
    5
    1
    30d
    EPS Estimate Drift
    90d ago$-0.33-33.6%
    60d ago$-0.33-33.6%
    30d ago$-0.32-30.0%
    7d ago$-0.24+0.0%
    Current$-0.24
    Revenue Consensus
    $182M
    Range$180M - $187M
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.30 - $0.04
    7 analysts
    Revenue Consensus
    $203M
    Range$196M - $215M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.24---
    Jun 26
    		$-0.13N/A+56.67%Beat+63.9%
    Mar 26
    		$-0.62$-0.51-21.57%Miss-100.0%
    Dec 25
    		$-0.22$-0.41+46.34%Beat+63.9%
    Sep 25
    		$-0.33$-0.42+21.43%Beat-17.9%
    Jun 25
    		$-0.36$-0.39+7.69%Beat-16.1%
    Mar 25
    		$-0.31$-0.46+32.61%Beat+13.9%
    Dec 24
    		$-0.61$-0.36-69.44%Miss-35.6%
    Sep 24
    		$-0.28$-0.33+15.15%Beat+39.1%
    Jun 24
    		$-0.31$-0.40+22.50%Beat+42.6%
    Mar 24
    		$-0.36$-0.42+14.29%Beat+28.0%
    Dec 23
    		$-0.45$-0.52+13.46%Beat-25.0%
    Sep 23
    		$-0.46$-0.52+11.54%Beat-84.0%
    Jun 23
    		$-0.54$-0.50-8.00%Miss-134.8%
    Mar 23
    		$-0.50$-0.34-47.06%Miss-1150.0%
    Dec 22
    		$-0.36$-0.30-20.00%Miss-44.0%
    Sep 22
    		$-0.25$-0.26+3.85%Beat-92.3%
    Jun 22
    		$-0.23$-0.14-64.29%Miss-64.3%
    Mar 22
    		$-0.04N/A+77.78%Beat+0.0%
    Dec 21
    		$-0.25$-0.10-150.00%Miss-725.0%
    Sep 21
    		$-0.13$-0.06-116.67%Miss-244.4%
    Jun 21
    		$-0.14$0.01-1500.00%Miss-800.0%
    Mar 21
    		$-0.04$0.01-500.00%Miss-200.0%
    Dec 20
    		$0.04N/A-66.67%Miss+0.0%
    Sep 20
    		$0.09$0.04+125.00%Beat+350.0%
    Jun 20
    		$0.02$0.01+100.00%Beat+300.0%
    Mar 20
    		$0.04$0.02+100.00%Beat+130.8%
    Dec 19
    		$0.04$0.02+100.00%Beat+123.5%
    Sep 19
    		$0.02$-0.04+150.00%Beat+115.4%
    Jun 19
    		$-0.01N/A+83.33%Beat+94.1%
    Mar 19
    		$-0.13$-0.15+13.33%Beat+43.5%
    Dec 18
    		$-0.17$-0.13-30.77%Miss-41.7%
    Sep 18
    		$-0.13$-0.14+7.14%Beat+0.0%
    Jun 18
    		$-0.17$-0.16-6.25%Miss+29.2%
    Mar 18
    		$-0.23$-0.13-76.92%Miss-9.5%
    Dec 17
    		$-0.12$-0.11-9.09%Miss+53.8%
    Sep 17
    		$-0.13$-0.14+7.14%Beat+66.7%
    Jun 17
    		$-0.24$-0.22-9.09%Miss-
    Mar 17
    		$-0.21$-0.20-5.00%Miss-
    Dec 16
    		$-0.26$-0.39+33.33%Beat-
    Sep 16
    		$-0.39$-0.31-25.81%Miss-

    Key Metrics

    Valuation
    P/E Ratio-13.58EV/EBITDA-6.92x
    Price/FCF-80.51xFCF Yield-1.24%
    Profitability
    Profit Margin-21.20%Operating Margin-5.75%
    ROE-43.20%ROIC-28.13%
    Financial Health
    Debt/Equity0.58xInterest CoverageN/A
    Current Ratio2.89xQuick Ratio2.70x
    Trading Statistics
    Beta0.98Avg Volume1.28M
    52-Week High$21.4552-Week Low$9.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.60
    SMA 20$17.24
    SMA 50$16.53
    SMA 200$14.23
    EMA 10$17.57
    EMA 20$17.29
    EMA 50$16.76
    EMA 200$15.25

    MACD

    Line: 0.35Signal: 0.32Hist: 0.03

    ADX

    ADX: 24.1+DI: 28.2-DI: 16.3

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$15.82

    Bollinger Bands

    Upper Band$18.62
    Lower Band$15.86
    %B Position1602%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    54.0

    Momentum Oscillators

    Stoch %K65.6
    Stoch %D69.8
    Williams %R-42.1
    ROC (10d)0.7%
    Momentum0.12
    CCI (20d)58.8
    MFI (14d)52.3

    Volatility Measures

    ATR (14d)$0.87(5.0%)
    StdDev (20d)0.69
    Hist Vol51.1%(High)

    Volume Flow

    VWAP$17.67
    OBV16.8M
    AD Line1.2M
    CMF (20d)0.313

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.7x
    VWMA (20d)$17.32

    Pivot Points

    R3$18.92
    R2$18.54
    R1$18.18
    Pivot Point$17.80
    S1$17.44
    S2$17.06
    S3$16.70

    Advanced Oscillators

    TSI8.78
    Ultimate Osc58.8
    KST82.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$183.58M$174.06M$174.35M$167.20M$158.81M$154.99M$161.27M$155.09M$150.36M$138.50M$133.78M$127.32M
    Cost of Revenue$41.11M$38.93M$42.16M$44.73M$41.47M$38.52M$33.47M$35.37M$34.65M$33.69M$32.56M$32.09M
    Gross Profit$142.48M$135.13M$132.19M$122.47M$117.33M$116.47M$127.80M$119.72M$115.70M$104.81M$101.23M$95.23M
    Operating Expenses$153.04M$202.55M$172.59M$158.50M$156.85M$154.34M$191.10M$151.81M$149.28M$146.33M$152.94M$153.47M
    R&D$51.45M$58.34M$60.91M$54.03M$55.83M$53.78M$51.21M$51.88M$54.95M$51.60M$54.31M$53.62M
    SG&A$39.91M$85.85M$43.02M$45.92M$43.95M$44.77M$72.48M$40.10M$37.71M$39.53M$39.45M$41.89M
    Operating Income$-10,562,000$-67,420,000$-40,393,000$-36,021,000$-39,521,000$-37,865,000$-63,304,000$-32,092,000$-33,580,000$-41,520,000$-51,716,000$-58,245,000
    Interest Income$-1,890,000$-1,838,000$-561,000$6.00M$4.54M$7.57M$8.10M$10.51M$10.85M$9.88M$13.18M$10.02M
    Interest Expense$1.89M$1.84M$561,000$0$0$0$0$0$0$0$0$0
    Income Before Tax$-12,452,000$-69,258,000$-40,954,000$-30,022,000$-34,979,000$-30,295,000$-55,206,000$-21,585,000$-22,729,000$-31,642,000$-38,534,000$-48,222,000
    Income Tax Expense$3.21M$1.88M$-16,455,000$7.25M$5.16M$4.02M$10.72M$8.98M$10.65M$7.12M$8.54M$1.26M
    Net Income$-15,658,000$-71,138,000$-24,499,000$-37,270,000$-40,139,000$-34,319,000$-65,922,000$-30,570,000$-33,375,000$-38,760,000$-47,079,000$-49,485,000
    EBITDA$-8,848,000$-65,913,000$-39,921,000$-38,760,000$-42,537,000$-41,194,000$-66,872,000$-36,371,000$-37,576,000$-44,086,000$-56,255,000$-62,133,000
    EBIT$-10,562,000$-67,420,000$-40,393,000$-36,021,000$-39,521,000$-37,865,000$-63,304,000$-32,092,000$-33,580,000$-41,520,000$-51,716,000$-58,245,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NVCR

    Government Contracts

    Gov Obligations (TTM)
    $10.82M
    Gov Obligations / Revenue
    1.5%
    Obligations YoY
    26.4%
    Active Awards
    263
    New Awards (TTM)
    241
    Avg Remaining Term
    2.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26326N0625Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 21, 2026
    36C25726K0213Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 3, 2026
    36C26326N0610Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 13, 2026
    36C26326N0600Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 6, 2026
    36C26126N0522Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 22, 2026
    36C25026F0510Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 4, 2026
    36C24726N0259Department of Veterans AffairsDepartment of Veterans Affairs$99497May 22, 2026
    36C25026F0469Department of Veterans AffairsDepartment of Veterans Affairs$99497May 5, 2026
    36C25726K0119Department of Veterans AffairsDepartment of Veterans Affairs$99497Mar 13, 2026
    36C26326N0515Department of Veterans AffairsDepartment of Veterans Affairs$99497May 6, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?

    NovoCure (NVCR) has received an upgraded Momentum Style Score of B and a Zacks Rank of #2 (Buy) due to recent upward earnings estimate revisions. While this indicates growing confidence in its near-term earnings and tumor treating fields platform, the core investment narrative, execution in new indications, and physician adoption remain key factors. The company recently raised its full-year net revenue guidance and narrowed losses, but investors should still consider the risks associated with reliance on a single technology.

    Simply Wall Street•8/22/26•
    Somewhat-Bullish

    Novocure | 8-K: Current report

    This article is a current report (8-K) filed by Novocure. The content is simply "Document", indicating that the full details of the 8-K filing would be contained within an attached document, which is not provided here.

    Moomoo•8/20/26•
    Neutral

    What’s Behind NovoCure (NVCR) Shares Climbing Today?

    NovoCure (NVCR) shares have seen recent positive momentum, with a 10.11% gain over the past month and 33.61% year-to-date, despite an 87.03% decline over five years. The company is considered 32.8% undervalued with a fair value of $26.07, driven by potential regulatory approvals for its TTFields therapy and expected market expansion in oncology. However, risks like slower adoption and reimbursement uncertainty could challenge this valuation.

    Simply Wall Street•8/18/26•
    Somewhat-Bullish

    What’s Behind NovoCure (NVCR) Shares Climbing Today?

    NovoCure (NVCR) shares have seen recent positive momentum, with a 10.11% gain over the last month, despite an 87.03% decline in total shareholder return over five years. The company is currently considered 32.8% undervalued, with a fair value of $26.07 compared to its recent close of $17.53, driven by potential regulatory approvals and market expansion for its TTFields therapy. However, risks like slower adoption and reimbursement uncertainty could challenge this valuation.

    Simply Wall Street•8/18/26•
    Somewhat-Bullish

    NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials Progress - Has The Bull Case Changed?

    NovoCure (NVCR) shares rose 8.5% following updates on its tumor treating fields (TTFields) pipeline, including devices like Optune Gio and Optune Lua, and progress in clinical trials for solid tumor cancers. While these advancements reinforce the long-term investment thesis for TTFields, the recent TRIDENT Phase 3 trial for glioblastoma did not meet its primary survival endpoint, tempering near-term expectations for broader adoption. Investors are encouraged to weigh the potential for scaling revenues against ongoing losses and uneven clinical outcomes.

    Simply Wall Street•8/13/26•
    Neutral

    Frequently Asked Questions About NVCR

    Does NVCR pay dividends?
    Novocure Ltd (NVCR) does not currently pay a regular dividend.
    What is NVCR's market cap?
    Novocure Ltd (NVCR) has a market capitalization of $2.08B with a current stock price of $17.65.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In